Vical Faced With Failure of Another Vaccine Trial
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.